CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Immuneering Presents Phase 3 Trial Design for Atebimetinib in Metastatic Pancreatic Cancer

By Public Technologies
  • Immuneering presented the design of its ongoing Phase 3 MAPKeeper 301 trial at ESMO on Oct. 25, 2026.
  • The trial tests atebimetinib with modified gemcitabine/nab-paclitaxel against standard chemotherapy as first-line treatment for metastatic pancreatic cancer.
  • Overall survival is the primary endpoint; the study aims to determine whether the combination extends survival compared with standard treatment.
  • Phase 2a results presented at ASCO in June 2026 showed encouraging survival outcomes, but comparisons with historical chemotherapy outcomes were not head-to-head.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260730PRIMZONEFULLFEED9852345) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk